What Pinnacle Biologics does

Pinnacle Biologics, Inc. is a privately held specialty pharmaceutical company founded in 2007 and headquartered in Bannockburn, Illinois (though incorporated under New York governing law). The company operates with a small employee base of 11-50 staff and is focused on revitalizing older pharmaceutical brands and enabling newer therapies, primarily in oncology. Its stated business model is to acquire, sustain, and commercially support therapies that larger manufacturers are unwilling or unable to continue financing, providing integrated sales, marketing, regulatory, and pharmacovigilance capabilities for niche oncology and rare disease products.

The company's core product is PHOTOFRIN (porfimer sodium) for injection, a photosensitizing agent used in photodynamic therapy (PDT). PHOTOFRIN is FDA-approved for three indications: palliation of esophageal cancer, treatment of microinvasive endobronchial non-small cell lung cancer (NSCLC), and ablation of high-grade dysplasia in Barrett's esophagus. The PHOTOFRIN and OPTIGUIDE trademarks are licensed inbound from Concordia Laboratories Inc. Photodynamic therapy works by activating the injected porfimer sodium with targeted light to treat cancerous or dysplastic tissue, and PHOTOFRIN represents the company's primary revenue-generating asset. Pinnacle distributes PHOTOFRIN directly in the United States through a dedicated specialty sales force targeting oncologists, pulmonologists, and gastroenterologists, with phone-based ordering and a Medical Information department whose contact emails route through advanzpharma.com — suggesting operational or corporate affiliation with Advanz Pharma.

The company generates revenue through pharmaceutical product sales of PHOTOFRIN, distributed through medical channels in the US. Pricing is not publicly disclosed and is negotiated through healthcare providers and payer systems. Marketing is conducted through a corporate website (pinnaclebiologics.com), a dedicated product website (photofrin.com), and a Medical Information contact center. No acquisition targets, M&A activity, or recent funding rounds beyond a $1.5M raise in December 2011 are evidenced. Leadership includes founder Viren Grover as Vice Chairman and Guillermo Herrera as Executive Chairman and CEO. Pinnacle is described as having "global operations" in its own materials, though direct distribution is currently US-only and the website is restricted to US residents.

Name

Pinnacle Biologics

Legal name

Pinnacle Biologics, Inc.

Website

https://pinnaclebiologics.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Pinnacle Biologics is a privately held US specialty pharmaceutical company that distributes PHOTOFRIN (porfimer sodium), an FDA-approved photodynamic therapy agent, to oncologists, pulmonologists, and gastroenterologists treating esophageal cancer, endobronchial NSCLC, and Barrett's esophagus dysplasia.

Ownership category

akta.pro rank

Product category

Specialty Oncology Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

akta.pro secondary industry

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)

Keywords

• Specialty pharmaceutical products
• Photodynamic therapy drugs
• Oncology pharmaceuticals
• Pharmaceutical brand revitalization
• Biologic drug distribution

Headquarters

HQ city

Deerfield

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Revenue generated through the sale of specialty pharmaceutical products, primarily PHOTOFRIN, distributed in the United States for oncology indications including esophageal cancer, endobronchial lung cancer, and Barrett's esophagus dysplasia.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Pinnacle Biologics commercializes specialty pharmaceutical products, anchored by PHOTOFRIN (porfimer sodium) for Injection, a photodynamic therapy agent indicated for palliation of esophageal cancer, treatment of microinvasive endobronchial non-small cell lung cancer, and ablation of high-grade dysplasia in Barrett's esophagus. The company distributes and supports these therapies in the United States through a dedicated specialty sales force, regulatory and pharmacovigilance infrastructure, and licensing of established brands such as PHOTOFRIN and OPTIGUIDE.

Product overview

Pinnacle Biologics is a specialty pharmaceutical company that revitalizes older brands and enables newer therapies to provide life-changing outcomes for patients worldwide. Their primary product is PHOTOFRIN® (porfimer sodium) for Injection, a photodynamic therapy used for treating esophageal cancer (palliation), endobronchial non-small cell lung cancer, and high-grade dysplasia in Barrett's esophagus.

Differentiator

Problem solved

Functional benefit

Brands

• Photofrin®: Photodynamic therapy drug (porfimer sodium) for injection used for treatment of esophageal cancer, endobronchial non-small-cell lung cancer, and high-grade dysplasia in Barrett's esophagus. Distributed in the United States by Pinnacle Biologics.

Products and services

• PHOTOFRIN (porfimer sodium) for Injection Photodynamic therapy agent indicated for the palliation of patients with completely or partially obstructing esophageal cancer, treatment of microinvasive endobronchial non-small cell lung cancer (NSCLC) where surgery and radiotherapy are not indicated, reduction of obstruction and palliation of symptoms in endobronchial NSCLC, and ablation of high-grade dysplasia in Barrett's esophagus. Distributed by Pinnacle Biologics in the United States for prescribing oncology, pulmonary, and gastroenterology specialists.

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Direct peers

• Advanz Pharma: European-headquartered specialty pharma focused on acquiring and revitalizing older critical medicines. The Pinnacle medical information email ([email protected]) and references to 'parent, subsidiaries, and affiliates' in Pinnacle's privacy policy strongly indicate Advanz is the parent/affiliate, operating an identical specialty revitalizer model.
• Concordia Laboratories Inc. Owner of the PHOTOFRIN and OPTIGUIDE trademarks, which it licenses to Pinnacle Biologics. Directly comparable as a specialty pharma entity commercializing porfimer sodium for the same oncology indications, with the same patient population and prescriber base.
• ANI Pharmaceuticals: Small US specialty pharma that acquires and revitalizes established drug brands with limited commercial support. Comparable in scale, business model (niche/specialty drug acquisition and direct sales), and customer base (specialty prescribers and institutions).
• Cumberland Pharmaceuticals: Small US specialty pharma with a focused portfolio of niche pharmaceutical products promoted through a dedicated specialty sales force. Comparable in size, go-to-market (specialty sales force targeting prescribers), and therapeutic positioning around under-served indications.

Broad incumbents

• Mallinckrodt Pharmaceuticals: Specialty pharma company operating a similar model of acquiring and supporting older or under-resourced therapies in niches such as oncology, immunology, and rare disease. Comparable in therapeutic areas (including oncology) and commercial approach of sustaining critical drugs larger manufacturers deprioritize.
• Jazz Pharmaceuticals: Established specialty pharma focused on oncology and rare diseases with a dedicated specialty sales force. Comparable in therapeutic focus (oncology, particularly hematology/oncology and rare cancers) and specialty distribution model, though operating at materially larger scale and broader portfolio.
• Hikma Pharmaceuticals: Specialty and generic pharma with a branded portfolio including niche oncology and hospital products. Comparable in operating a specialty sales force for under-resourced brands and selling into hospital/oncology channels, though at much larger scale and across many therapy areas.
• Bausch Health: Large specialty pharma with diversified specialty franchises including oncology-adjacent products. Comparable in commercializing specialty and hospital-channel products through dedicated sales infrastructure, though covering a much wider portfolio and broader geographic footprint.

Emerging players

• Steba Biotech: Biotech developing padeliporfin-based vascular-targeted photodynamic therapy (TOOKAD) for prostate cancer and other solid tumors. Comparable as a developer and marketer of an injectable photosensitizer for oncology indications, directly overlapping with Pinnacle's PDT technology category.
• Theralase Technologies: Canadian biotech developing photodynamic therapy compounds for oncology and infectious disease. Comparable as a PDT-focused player operating in the same underlying technology category (light-activated photosensitizers) as PHOTOFRIN, though focused on next-generation agents.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pinnacle-biologics-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pinnacle Biologics